Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas — GRADIENT  

Hypercortisolism Clinical Trial

Official title: Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients With Cortisol-Secreting Adrenal Adenomas or Hyperplasia: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Relacorilant

Status Active, not recruiting

Clinical Trial Summary

This is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, and safety of relacorilant to treat hypercortisolism in patients with cortisol-secreting adrenal adenoma or hyperplasia associated with diabetes mellitus/ impaired glucose tolerance and/or uncontrolled systolic hypertension.

Clinical Trial Description

This Phase 3 study patients will be randomized in a 1:1 ratio to treatment with relacorilant (active drug) or placebo. Patients will receive relacorilant or placebo for 22 weeks. Patients who complete the study may also be eligible to roll over into an extension study. ;

Related Conditions & MeSH terms

• Adenoma
• Adrenocortical Adenoma
• Adrenocortical Hyperfunction
• Cushing Syndrome
• Hypercortisolism

• NCT number: NCT04308590
• Study type: Interventional
• Source: Corcept Therapeutics
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: July 27, 2020
• Completion date: September 27, 2024